Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells

Laryngoscope

Volumn 123, Issue 6, 2013, Pages 1416-1423

  Xie, Tong Xin ^a   Zhou, Ge ^a   Zhao, Mei ^a   Sano, Daisuke ^a   Jasser, Samar A ^a   Brennan, Richard G ^b   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anoikis; head and neck squamous cell carcinoma; orthotopic; p53

Indexed keywords

AGAR; FLUOROURACIL; HYDROXYL GROUP; OXYGEN; PROLINE; PROTEIN P53; SERINE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; CANCER CELL; CANCER GROWTH; CODON; CRYSTAL STRUCTURE; GAIN OF FUNCTION MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYDROPHOBICITY; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT TANDEM REPEAT; THERMODYNAMICS;

ANIMALS; ANOIKIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CODON; DISEASE PROGRESSION; DNA, NEOPLASM; HEAD AND NECK NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; PROLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878122828     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23846     Document Type: Article

References (31)

1. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
2. Blons H, Laurent-Puig P,. TP53 and head and neck neoplasms. Hum Mutat 2003; 21: 252-257.
3. Hainaut P, Hollstein M,. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
4. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
5. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P,. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614.
6. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2009; 16: 1-12.
7. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003; 100: 8424-8429.
8. Willis A, Jung EJ, Wakefield T, Chen X,. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004; 23: 2330-2338.
9. Brosh R, Rotter V,. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
10. Wolf D, Harris N, Rotter V,. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 1984; 38: 119-126.
11. Shaulsky G, Goldfinger N, Rotter V,. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 1991; 51: 5232-5237.
12. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42-46.
13. Sigal A, Rotter V,. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2002; 60: 6788-6793.
14. Oren M, Rotter V,. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
15. Frisch SM, Francis H,. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
16. Swan EA, Jasser SA, Holsinger FC, Doan D, Bucana C, Myers JN,. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 2003; 39: 648-655.
17. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ,. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002; 8: 293-298.
18. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66: 3188-3196.
19. Cheng H, Liu P, Wang ZC, et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009; 2: ra35.
20. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH,. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998; 143: 547-560.
21. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P,. Anoikis: an emerging hallmark in health and diseases. J Pathol 2012; 226: 380-393.
22. Sano D, Xie TX, Ow TJ, et al. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 2011; 17: 6658-6670.
23. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW,. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002; 51: 59-72.
24. Campomenosi P, Monti P, Aprile A, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001; 20: 3573-3579.
25. Monti P, Campomenosi P, Ciribilli Y, et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 2003; 22: 5252-5260.
26. Dearth LR, Qian H, Wang T, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007; 28: 289-298.
27. Nesslinger NJ, Shi XB, deVere White RW,. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003; 63: 2228-2233.
28. Vinall RL, Tepper CG, Shi XB, et al. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 2006; 25: 2082-2093.
29. Cho Y, Gorina S, Jeffrey PD, Pavletich NP,. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
30. Bullock AN, Fersht AR,. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
31. Walker DR, Bond JP, Tarone RE, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999; 18: 211-218.